Article Details

Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management - OncLive

Retrieved on: 2025-02-21 21:19:48

Tags for this article:

Click the tags to see associated articles and topics

Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management - OncLive. View article details on hiswai:

Excerpt

Lorlatinib (Lorbrena) has become the frontline standard of care for patients ... He also advocated for a measured, patient-centered approach to ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up